{"id":"tetracosactide","rwe":[{"pmid":"41644156","year":"2026","title":"Determining the comparative pharmacodynamic equivalence of a non-invasive diagnostic test for patients with adrenal insufficiency using a randomised 2-way crossover trial: the STARLIT-3 study protocol.","finding":"","journal":"BMJ open","studyType":"Clinical Study"},{"pmid":"41365708","year":"2026","title":"No effect of tetracosactide for treatment of postdural puncture headaches in parturient women: many unanswered questions. Response to Br J Anaesth 2025; 135: 1102-3.","finding":"","journal":"British journal of anaesthesia","studyType":"Clinical Study"},{"pmid":"40917330","year":"2025","title":"Adrenal Insufficiency after Steroid Therapy in Children with Steroid-Sensitive Nephrotic Syndrome: A Cross-sectional Study.","finding":"","journal":"Indian journal of endocrinology and metabolism","studyType":"Clinical Study"},{"pmid":"40835197","year":"2025","title":"Adrenocorticotropic hormone combined with vigabatrin as a second-line therapy for West syndrome.","finding":"","journal":"Arquivos de neuro-psiquiatria","studyType":"Clinical Study"},{"pmid":"40769842","year":"2025","title":"No effect of tetracosactide for treatment of postdural puncture headaches in parturient women: prophylactic use of cosyntropin following accidental dural puncture. Comment on Br J Anaesth 2025; 135: 148-54.","finding":"","journal":"British journal of anaesthesia","studyType":"Clinical Study"}],"_fda":{"id":"2a4b497c-9753-436b-8dc2-93440ccf680e","set_id":"0c424fac-b114-41f6-aba8-cf710a34c26c","openfda":{"nui":["M0000499","N0000175941"],"unii":["72YY86EA29"],"route":["INTRAMUSCULAR","INTRAVENOUS","PARENTERAL"],"spl_id":["2a4b497c-9753-436b-8dc2-93440ccf680e"],"brand_name":["Cortrosyn"],"spl_set_id":["0c424fac-b114-41f6-aba8-cf710a34c26c"],"package_ndc":["0404-9839-99"],"product_ndc":["0404-9839"],"generic_name":["CORTROSYN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Adrenocorticotropic Hormone [CS]"],"substance_name":["COSYNTROPIN"],"pharm_class_epc":["Adrenocorticotropic Hormone [EPC]"],"manufacturer_name":["Henry Schein, Inc."],"application_number":["NDA016750"],"original_packager_product_ndc":["0548-5900"]},"version":"6","description":["11 Description Cosyntropin is an adrenocorticotropic hormone (ACTH). Cosyntropin is synthetic beta 1 - 24 corticotropin, a synthetic subunit of ACTH. It is an open chain polypeptide containing, the first 24 of the 39 amino acids of natural ACTH in sequence from N terminal. The sequence of amino acids in the 1 - 24 compound is as follows: The empirical formula is C 136 H 210 N 40 O 31 S with a molecular weight of 2934 g/mol. CORTROSYN (cosyntropin) for Injection is a sterile lyophilized powder in single-dose vials containing 0.25 mg of cosyntropin and 10 mg of mannitol. Sodium Hydroxide and Glacial acetic acid may be used to adjust pH. Image2.jpg"],"how_supplied":["16 How Supplied/Storage and Handling How Supplied CORTROSYN (cosyntropin) for injection 0.25 mg, in a single-dose vial for reconstitution. Box contains 10 single-dose vials NDC 0548-5900-00 Storage and Handling Store at 20º to 25ºC (68º to 77ºF); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. CORTROSYN injection is intended as a single-dose injection and contains no antimicrobial preservative. Any unused portion should be discarded. Product repackaged by: Henry Schein, Inc., Bastian, VA 24314 From Original Manufacturer/Distributor's NDC and Unit of Sale To Henry Schein Repackaged Product NDC and Unit of Sale Total Strength/Total Volume (Concentration) per unit NDC 0548-5900-00 Box of 10 vials NDC 0404-9839-99 1 Vial in a bag (Vial bears NDC 0548-5900-00) 0.25 mg"],"effective_time":"20250617","adverse_reactions":["6 Adverse Reactions Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of CORTROSYN: anaphylactic reaction bradycardia tachycardia hypertension peripheral edema rash Most common adverse reactions are: anaphylactic reaction, bradycardia, tachycardia, hypertension, peripheral edema, and rash (6) To report SUSPECTED ADVERSE REACTIONS, contact Amphastar Pharmaceuticals, Inc. at 1-800-423-4136 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 Contraindications CORTROSYN is contraindicated in patients with a history of hypersensitivity to cosyntropin or to any excipients of CORTROSYN. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)]. CORTROSYN is contraindicated in patients with a history of hypersensitivity to cosyntropin or to any excipients of CORTROSYN. Reactions have included anaphylaxis. (4, 5.1)"],"drug_interactions":["7 Drug Interactions 7.1 Drug Effects on Plasma Cortisol Levels Accuracy of the test results can be affected by concomitant medications. Plasma cortisol levels and subsequent diagnosis of adrenocortical insufficiency following CORTROSYN administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels [see Dosage and Administration (2.1) and Warnings and Precautions (5.2)]. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on the day of CORTROSYN testing. Long-acting glucocorticoids may need to be stopped for a longer period before CORTROSYN testing. Estrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before CORTROSYN testing to allow cortisol binding globulin levels to return to levels within the reference range. Alternatively, concomitant measurement of cortisol binding globulin at the time of testing can be done; if cortisol binding globulin levels are elevated, plasma total cortisol levels are considered inaccurate. Drug effects on plasma cortisol levels: ◦ Accuracy of the test results can be affected by concomitant medications.◦ Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on day of CORTROSYN testing. Long-acting glucocorticoids may need to be stopped for a longer period before CORTROSYN testing. (7)◦ Estrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before CORTROSYN testing. (7) See 17 for PATIENT COUNSELING INFORMATION Revised 12/2023"],"how_supplied_table":["<table width=\"100%\"><caption> Product repackaged by: Henry Schein, Inc., Bastian, VA 24314</caption><tbody><tr><td>From Original Manufacturer/Distributor&apos;s NDC and Unit of Sale</td><td>To Henry Schein Repackaged Product NDC and Unit of Sale</td><td>Total Strength/Total Volume (Concentration) per unit</td></tr><tr><td>NDC 0548-5900-00 Box of 10 vials</td><td>NDC 0404-9839-99 1 Vial in a bag (Vial bears NDC 0548-5900-00)</td><td> 0.25 mg</td></tr></tbody></table>"],"clinical_pharmacology":["12 Clinical Pharmacology 12.1 Mechanism of Action Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of CORTROSYN is similar to that of purified natural ACTH. It has been established that 0.25 mg of CORTROSYN will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. This dose of CORTROSYN will produce maximal secretion of 17-OH corticosteroids, 17-ketosteroids and/or 17-ketogenic steroids. 12.2 Pharmacodynamics Animal, human and synthetic ACTH (1-39) which all contain 39 amino acids exhibit similar immunologic activity. This activity resides in the C-terminal portion of the molecule and the 22-39 amino acid residues exhibit the greatest degree of antigenicity. In contrast, synthetic polypeptides containing 1-19 or fewer amino acids have no detectable immunologic activity. Those containing 1-26, 1-24 or 1-23 amino acids have very little immunologic although full biologic activity. This property of CORTROSYN assumes added importance in view of the known antigenicity of natural ACTH."],"indications_and_usage":["1 Indications and Usage CORTROSYN is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. CORTROSYN is an adrenocorticotropin hormone indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. (1)"],"warnings_and_cautions":["5 Warnings and Precautions 5.1 Hypersensitivity to CORTROSYN Injection CORTROSYN injection hypersensitivity reactions including anaphylaxis have been reported. Monitor patients for hypersensitivity reactions and treat as needed. 5.2 Diagnostic Inaccuracies Cortisol levels and subsequent diagnosis of adrenocortical insufficiency following CORTROSYN administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels. Glucocorticoids and spironolactone may result in falsely elevated cortisol levels. Stop these drugs on the day of CORTROSYN testing. Long-acting glucocorticoids may need to be stopped for a longer period before CORTROSYN testing [see Dosage and Administration (2.1) and Drug Interactions (7)]. Estrogen-containing drugs increase cortisol binding globulin levels which can increase plasma total cortisol levels. To obtain accurate plasma total cortisol levels, stop estrogen containing drugs four to six weeks before CORTROSYN testing to allow cortisol binding globulin levels to return to levels within the reference range [see Dosage and Administration (2.1) and Drug Interactions (7)]. Alternatively, concomitant measurement of cortisol binding globulin at the time of testing can be done; if cortisol binding globulin levels are elevated, plasma total cortisol levels are considered inaccurate. Any condition that elevates or lowers cortisol binding globulin levels may increase or decrease plasma total cortisol levels, respectively. Cortisol binding globulin levels can be low in cirrhosis or nephrotic syndrome. Measure cortisol binding globulin levels as necessary to ensure accuracy of interpretation of plasma total cortisol levels. Hypersensitivity: reactions including anaphylaxis have been reported. Monitor patients for hypersensitivity reactions and treat as needed. (5.1) Diagnostic Inaccuracies: Cortisol levels and subsequent diagnosis of adrenocortical insufficiency following CORTROSYN administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels. Any condition that elevates or lowers cortisol binding globulin levels may increase or decrease plasma total cortisol levels, respectively. (2.1, 5.2, 7)"],"nonclinical_toxicology":["13 Nonclinical Toxicology 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of cosyntropin have not been conducted. Studies to evaluate mutagenic potential or impairment of fertility in animals have not been conducted."],"spl_unclassified_section":["Highlights of Prescribing Information These highlights do not include all the information needed to use CORTROSYN® safely and effectively. See full prescribing information for CORTROSYN®. CORTROSYN (cosyntropin) for injection, for intravenous or intramuscular use Initial U.S. Approval: 2008","17 Patient Counseling Information Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information). Hypersensitivity Reactions, Including Anaphylaxis Inform patients and/or caregivers of the early signs of hypersensitivity reactions including rash, hives, itching, facial swelling, tightness of the chest, and wheezing [see Contraindications (4), Warnings and Precautions (5.1)]. Drug Interference with CORTROSYN Testing Advise patients and/or caregivers to stop taking glucocorticoids and spironolactone on the day of CORTROSYN testing. However, for patients taking long-acting glucocorticoids, advise them to stop for longer periods before CORTROSYN testing. Advise patients to stop taking estrogen-containing drugs four to six weeks before CORTROSYN testing [see Dosage and Administration (2.1), Warnings and Precautions (5.2), and Drug Interactions (7)]. Manufactured by: Amphastar Pharmaceuticals, Inc. Rancho Cucamonga, CA 91730 U.S.A. Rev. 12-23"],"dosage_and_administration":["2 Dosage and Administration 2.1 Important Information Before Conducting CORTROSYN TESTING In general, stop glucocorticoids and spironolactone on the day of CORTROSYN testing. However, long-acting glucocorticoids may need to be stopped for a longer period before CORTROSYN testing [see Warnings and Precautions (5.2), Drug Interactions (7)]. Stop estrogen-containing drugs four to six weeks before CORTROSYN testing [see Warnings and Precautions (5.2), Drug Interactions (7)]. 2.2 Recommended Dose for Adults The recommended dose of CORTROSYN in adults is 0.25 mg to be administered by intravenous or intramuscular injection. 2.3 Recommended Dose for Pediatric Patients The recommended dose of CORTROSYN in pediatric patients, aged birth to 17 years, to be administered by intravenous or intramuscular injection is presented in Table 1. 2.4 Reconstitution Instructions Aseptically reconstitute the lyophilized powder in the vial using 1 mL of 0.9% Sodium Chloride Injection, USP and gently swirl. After reconstitution, the final concentration of CORTROSYN reconstituted solution is 0.25 mg/mL. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted CORTROSYN solution should be clear and colorless, and free of particulates. If CORTROSYN solution is cloudy or contains particulates, do not administer. If the CORTROSYN reconstituted solution is not used immediately, discard the unused CORTROSYN reconstituted solution. 2.5 Administration Information CORTROSYN may be administered by intramuscular or intravenous injection. Obtain blood sample for baseline serum cortisol. Obtain blood samples again for assessment of cortisol levels exactly 30 minutes and 60 minutes after administration of CORTROSYN. 2.6 Interpretation of Plasma Cortisol Levels after CORTROSYN Injection Stimulated plasma cortisol levels of less than 18 mcg/dL at 30- or 60-minutes post CORTROSYN injection are suggestive of adrenocortical insufficiency. Cutoff values for exclusion of adrenocortical insufficiency may vary according to the assay used. Test results can be affected by concomitant medications and certain medical conditions [see Warnings and Precautions (5.2)]. In general, stop glucocorticoids and spironolactone on the day of CORTROSYN testing. For long-acting glucocorticoids, stop for a longer period before CORTROSYN testing. (2.1) For adults, the recommended dose is 0.25 mg to be administered by intravenous or intramuscular injection. (2.2) For pediatric patients, the recommended dose to be administered by intravenous or intramuscular injection is (2.3): ◦ 0.125 mg for patients birth to less than 2 years of age ◦ 0.25 mg for patients 2 to 17 years of age Obtain blood samples for serum cortisol level at baseline and exactly 30 and 60 minutes after CORTROSYN administration. (2.5) See Full Prescribing Information for reconstitution and interpretation of cortisol levels information. (2.4, 2.6) Image1.jpg"],"spl_product_data_elements":["Cortrosyn Cortrosyn Cosyntropin Cosyntropin"],"dosage_forms_and_strengths":["3 Dosage Forms and Strengths For Injection: 0.25 mg of cosyntropin as a lyophilized powder in a single-dose vial for reconstitution. For injection: 0.25 mg of cosyntropin as a lyophilized powder in single-dose vial for reconstitution (3)"],"use_in_specific_populations":["8 Use in Specific Populations 8.1 Pregnancy Risk Summary Available data from case reports over decades of use with cosyntropin during pregnancy have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Unidentified adrenal insufficiency can result in adverse maternal or fetal outcomes (see Clinical Considerations). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk for major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Unidentified adrenal insufficiency during pregnancy can result in maternal and/or fetal death; therefore, the diagnosis of suspected adrenal insufficiency during pregnancy should not be delayed. 8.2 Lactation Risk Summary There are no data on the presence of cosyntropin in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CORTROSYN and any potential adverse effects on the breastfed infant from CORTROSYN or from the underlying maternal condition. 8.4 Pediatric Use CORTROSYN is approved for use in pediatric patients [see Dosage and Administration (2.3)]."],"package_label_principal_display_panel":["Sample Package Label Label1.jpg"]},"tags":[{"label":"Adrenocorticotropic Hormone","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Melanocortin receptor 4","category":"target"},{"label":"MC4R","category":"gene"},{"label":"MC2R","category":"gene"},{"label":"H01AA02","category":"atc"},{"label":"Parenteral","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Adrenal cortical hypofunction","category":"indication"},{"label":"Cosyntropin preparation","category":"indication"},{"label":"Diagnostic Test for Secondary Adrenocortical Insufficiency","category":"indication"},{"label":"Amphastar Pharms Inc","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":107.331,"date":"","count":21,"signal":"Foetal growth restriction","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=107)"},{"llr":57.359,"date":"","count":19,"signal":"Hypoglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=57)"},{"llr":41.749,"date":"","count":5,"signal":"Adrenal haematoma","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=42)"}],"commonSideEffects":[{"effect":"hypertension","drugRate":"reported","severity":"unknown"},{"effect":"peripheral edema","drugRate":"reported","severity":"unknown"},{"effect":"rash","drugRate":"reported","severity":"unknown"},{"effect":"tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"bradycardia","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Cosyntropin for Injection should be given to pregnant woman only if clearly needed.","Paediatric use":"See DOSAGE AND ADMINISTRATION section."}},"trials":[],"aliases":[],"company":"Amphastar Pharms Inc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tetracosactide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:12:47.309871+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:13:14.389123+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:53.905974+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tetracosactide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:54.676781+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:12:45.097461+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:12:45.097555+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:13:06.049075+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:12:45.097586+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Melanocortin receptor 2 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:55.426712+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103784/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:55.337349+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA016750","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:12:45.097598+00:00"}},"allNames":"cortrosyn","offLabel":[],"synonyms":["corticotropin (1-24)","cosyntropin","tetracosactrin","tetracosapeptide","tetracosactide","tetracosactide acetate","tetracosactrin zinc"],"timeline":[{"date":"1970-04-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Amphastar Pharms Inc)"}],"aiSummary":"Cortrosyn is a medication that acts as an agonist to the melanocortin receptor 2, specifically targeting the adrenocorticotropic hormone receptor. It is used as a diagnostic agent in the ACTH stimulation test and has been studied for various conditions, including post-dural puncture headache and type 2 diabetes.","approvals":[{"date":"1970-04-22","orphan":false,"company":"AMPHASTAR PHARMS INC","regulator":"FDA"}],"brandName":"Cortrosyn","ecosystem":[{"indication":"Adrenal cortical hypofunction","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Cosyntropin preparation","otherDrugs":[],"globalPrevalence":null},{"indication":"Diagnostic Test for Secondary Adrenocortical Insufficiency","otherDrugs":[{"name":"metyrapone","slug":"metyrapone","company":"Hra Pharma"}],"globalPrevalence":null}],"mechanism":{"target":"Melanocortin receptor 4","novelty":"Follow-on","targets":[{"gene":"MC4R","source":"DrugCentral","target":"Melanocortin receptor 4","protein":"Melanocortin receptor 4"},{"gene":"MC2R","source":"DrugCentral","target":"Adrenocorticotropic hormone receptor","protein":"Adrenocorticotropic hormone receptor"}],"modality":"Peptide","drugClass":"Adrenocorticotropic Hormone [EPC]","explanation":"","oneSentence":"","technicalDetail":"Cortrosyn, a synthetic analogue of adrenocorticotropic hormone (ACTH), binds to the melanocortin receptor 4 (MC4R) on the surface of corticotroph cells in the pituitary gland, stimulating the release of adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal glands to produce cortisol."},"commercial":{"launchDate":"1970","_launchSource":"DrugCentral (FDA 1970-04-22, AMPHASTAR PHARMS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4516","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=tetracosactide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tetracosactide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:52:05.948106","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:13:14.389811+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"corticotropin","drugSlug":"corticotropin","fdaApproval":"1950-07-03","patentExpiry":"Oct 27, 2043","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"tetracosactide","indications":{"approved":[{"id":"tetracosactide-adrenocortical-insufficiency-s","name":"Adrenocortical insufficiency screening","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":"In combination with other diagnostic tests","brandNameForIndication":"Cortrosyn"}],"offLabel":[{"name":"West syndrome","source":"DrugCentral","drugName":"tetracosactide"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"corticotropin","brandName":"corticotropin","genericName":"corticotropin","approvalYear":"1950","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05149638","phase":"NA","title":"Updated Diagnostic Cortisol Values for Adrenal Insufficiency","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-02-03","conditions":["Adrenal Insufficiency"],"enrollment":90,"completionDate":"2027-12-01"},{"nctId":"NCT04546126","phase":"EARLY_PHASE1","title":"Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)","status":"RECRUITING","sponsor":"Benjamin Viglianti","startDate":"2021-11-01","conditions":["Radiotracer","Hypertension","Cholesterol"],"enrollment":24,"completionDate":"2026-12"},{"nctId":"NCT02339506","phase":"NA","title":"Stress and the Nervous System","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-04","conditions":["Autonomic Nervous System","Baroreflex","Stress, Physiological"],"enrollment":23,"completionDate":"2020-11"},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":["Sleep Restriction"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":["Sleep Restriction"],"enrollment":5,"completionDate":"2026-06-24"},{"nctId":"NCT02813655","phase":"PHASE2","title":"Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":["Post-dural Puncture Headache"],"enrollment":46,"completionDate":"2022-11-21"},{"nctId":"NCT06190158","phase":"EARLY_PHASE1","title":"Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-05-15","conditions":["Type 2 Diabetes","Chronic Kidney Diseases"],"enrollment":125,"completionDate":"2029-07-31"},{"nctId":"NCT04642391","phase":"","title":"Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2021-08-02","conditions":["Cirrhosis","Adrenal Insufficiency"],"enrollment":76,"completionDate":"2024-06-30"},{"nctId":"NCT03514589","phase":"PHASE2","title":"NeSST2: The Development of a Noninvasive Short Synacthen Test","status":"RECRUITING","sponsor":"Sheffield Children's NHS Foundation Trust","startDate":"2012-10-12","conditions":["Adrenal Suppression"],"enrollment":12,"completionDate":"2025-12-01"},{"nctId":"NCT02818660","phase":"NA","title":"Mass Spectrometry Based Cutoffs for Cortisol After Stimulation Tests","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2016-05-21","conditions":["Adrenal Insufficiency"],"enrollment":232,"completionDate":"2017-12-21"},{"nctId":"NCT04461535","phase":"NA","title":"Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2020-07-08","conditions":["Primary Aldosteronism"],"enrollment":228,"completionDate":"2023-02-20"},{"nctId":"NCT03793114","phase":"NA","title":"Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease","status":"UNKNOWN","sponsor":"University of Bergen","startDate":"2018-09-26","conditions":["Primary Adrenal Insufficiency"],"enrollment":200,"completionDate":"2025-12"},{"nctId":"NCT03905603","phase":"EARLY_PHASE1","title":"Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2019-10-08","conditions":["Polycystic Ovary Syndrome"],"enrollment":144,"completionDate":"2026-05-01"},{"nctId":"NCT01421797","phase":"NA","title":"Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2006-10-10","conditions":["Hyperandrogenemia","Polycystic Ovary Syndrome","Obesity"],"enrollment":84,"completionDate":"2024-12"},{"nctId":"NCT01764711","phase":"NA","title":"Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2013-01","conditions":["Postural Tachycardia Syndrome"],"enrollment":13,"completionDate":"2020-12-31"},{"nctId":"NCT03368066","phase":"PHASE3","title":"Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2018-01-29","conditions":["Adrenal Insufficiency","Cirrhosis","Spur Cell Anemia","Lecithin Acyltransferase Deficiency"],"enrollment":100,"completionDate":"2019-03-12"},{"nctId":"NCT03347526","phase":"PHASE3","title":"A Novel Approach to Infantile Spasms","status":"SUSPENDED","sponsor":"University of Colorado, Denver","startDate":"2018-04-19","conditions":["Infantile Spasm"],"enrollment":394,"completionDate":"2021-08"},{"nctId":"NCT03400852","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy","status":"TERMINATED","sponsor":"Mallinckrodt ARD LLC","startDate":"2018-07-27","conditions":["Muscular Dystrophy, Duchenne"],"enrollment":44,"completionDate":"2020-02-25"},{"nctId":"NCT00851942","phase":"PHASE4","title":"Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2008-09","conditions":["Healthy","Adrenal Insufficiency","Hypopituitarism"],"enrollment":165,"completionDate":"2013-01-31"},{"nctId":"NCT01062568","phase":"PHASE3","title":"The Adrenal Contribution to Androgen Production in Girls During Puberty","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-02","conditions":["Development"],"enrollment":50,"completionDate":"2014-07"},{"nctId":"NCT03752190","phase":"PHASE4","title":"Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2019-07","conditions":["Adrenal Insufficiency"],"enrollment":0,"completionDate":"2020-12-31"},{"nctId":"NCT03709381","phase":"EARLY_PHASE1","title":"Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2017-10-01","conditions":["Adrenal Insufficiency","Osteopenia, Osteoporosis","Steroid Suppression of ACTH Secretion"],"enrollment":10,"completionDate":"2019-01-31"},{"nctId":"NCT03083834","phase":"NA","title":"Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients","status":"UNKNOWN","sponsor":"Bnai Zion Medical Center","startDate":"2017-03-14","conditions":["Adrenal Insufficiency","Adrenal Cancer"],"enrollment":50,"completionDate":"2019-12-31"},{"nctId":"NCT03074123","phase":"NA","title":"Cortisol Response to Low Dose Cosyntropin Stimulation Test in the Late Afternoon","status":"COMPLETED","sponsor":"Bnai Zion Medical Center","startDate":"2017-04-01","conditions":["Adrenal Insufficiency"],"enrollment":20,"completionDate":"2018-08-01"},{"nctId":"NCT01422707","phase":"EARLY_PHASE1","title":"Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2018-01-19","conditions":["Hyperandrogenemia","Obesity","Polycystic Ovary Syndrome"],"enrollment":0,"completionDate":"2018-07-17"},{"nctId":"NCT01422733","phase":"EARLY_PHASE1","title":"Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2018-06-01","conditions":["Hyperandrogenemia","Obesity","Polycystic Ovary Syndrome"],"enrollment":0,"completionDate":"2018-07-17"},{"nctId":"NCT01422096","phase":"EARLY_PHASE1","title":"Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2018-06-01","conditions":["Hyperandrogenemia","Obesity","Polycystic Ovary Syndrome"],"enrollment":0,"completionDate":"2018-07-17"},{"nctId":"NCT00989781","phase":"NA","title":"Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":["Polycystic Ovary Syndrome"],"enrollment":41,"completionDate":"2013-09"},{"nctId":"NCT01673087","phase":"PHASE1","title":"Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-10","conditions":["Stress"],"enrollment":256,"completionDate":"2017-08-15"},{"nctId":"NCT02368379","phase":"NA","title":"Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2014-03","conditions":["Prader Willi Syndrome","Adrenal Insufficiency"],"enrollment":23,"completionDate":"2016-08"},{"nctId":"NCT01428336","phase":"NA","title":"Value of 25 mcg Cortrosyn Stimulation Test","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2011-09","conditions":["Adrenal Insufficiency"],"enrollment":22,"completionDate":"2015-01"},{"nctId":"NCT02394457","phase":"PHASE4","title":"Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache","status":"COMPLETED","sponsor":"United States Naval Medical Center, San Diego","startDate":"2010-08","conditions":["Postdural Puncture Headache"],"enrollment":29,"completionDate":"2014-04"},{"nctId":"NCT00542841","phase":"NA","title":"Examining Genetic Differences Among People With 21-Hydroxylase Deficiency","status":"COMPLETED","sponsor":"Maria I. New","startDate":"2007-08","conditions":["21-hydroxylase Deficiency"],"enrollment":99,"completionDate":"2009-03"},{"nctId":"NCT01839812","phase":"PHASE1","title":"Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-03","conditions":["Adrenal Cortex Diseases","Infant Morbidity"],"enrollment":35,"completionDate":"2013-06"},{"nctId":"NCT01371526","phase":"PHASE4","title":"Revival of Stem Cells in Addison's Study","status":"COMPLETED","sponsor":"Newcastle University","startDate":"2010-09","conditions":["Adrenal Failure"],"enrollment":13,"completionDate":"2012-09"},{"nctId":"NCT00694863","phase":"PHASE2","title":"Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-07","conditions":["Idiopathic Membranous Nephropathy"],"enrollment":20,"completionDate":"2012-12"},{"nctId":"NCT00744588","phase":"","title":"Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-08","conditions":["Alcohol Dependence"],"enrollment":75,"completionDate":"2012-03"},{"nctId":"NCT00975078","phase":"PHASE4","title":"Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-05","conditions":["Adrenal Gland Hypofunction"],"enrollment":39,"completionDate":"2009-10"},{"nctId":"NCT00415701","phase":"PHASE4","title":"Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-11","conditions":["Coronary Artery Disease","Mitral Valve Regurgitation"],"enrollment":130,"completionDate":"2009-12"},{"nctId":"NCT00598377","phase":"NA","title":"Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2006-09","conditions":["Autosomal Dominant Polycystic Kidney Disease"],"enrollment":49,"completionDate":"2007-09"},{"nctId":"NCT00006270","phase":"","title":"Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"1998-02","conditions":["Brain Injury","Craniocerebral Trauma"],"enrollment":32,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cosyntropin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Cortrosyn"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"COSYNTROPIN"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cosyntropin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"PARENTERAL","productName":"Cortrosyn"}]},"crossReferences":{"NUI":"N0000146844","MMSL":"132939","NDDF":"002115","UNII":"72YY86EA29","VUID":"4018522","CHEBI":"CHEBI:3901","VANDF":"4018522","INN_ID":"2255","RXNORM":"2890","UMLSCUI":"C0010192","chemblId":"CHEMBL2103784","ChEMBL_ID":"CHEMBL2103784","KEGG_DRUG":"D00284","DRUGBANK_ID":"DB01284","PUBCHEM_CID":"16133802","SNOMEDCT_US":"325824002","IUPHAR_LIGAND_ID":"6965","MESH_DESCRIPTOR_UI":"D003366"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1970-","companyName":"Amphastar Pharms Inc","relationship":"Original Developer"}],"publicationCount":194,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"H01AA02","allCodes":["H01AA02"]},"biosimilarFilings":[],"originalDeveloper":"Amphastar Pharms Inc","recentPublications":[{"date":"2026 Feb 5","pmid":"41644156","title":"Determining the comparative pharmacodynamic equivalence of a non-invasive diagnostic test for patients with adrenal insufficiency using a randomised 2-way crossover trial: the STARLIT-3 study protocol.","journal":"BMJ open"},{"date":"2026 Feb","pmid":"41365708","title":"No effect of tetracosactide for treatment of postdural puncture headaches in parturient women: many unanswered questions. Response to Br J Anaesth 2025; 135: 1102-3.","journal":"British journal of anaesthesia"},{"date":"2025 Jul-Aug","pmid":"40917330","title":"Adrenal Insufficiency after Steroid Therapy in Children with Steroid-Sensitive Nephrotic Syndrome: A Cross-sectional Study.","journal":"Indian journal of endocrinology and metabolism"},{"date":"2025 Aug","pmid":"40835197","title":"Adrenocorticotropic hormone combined with vigabatrin as a second-line therapy for West syndrome.","journal":"Arquivos de neuro-psiquiatria"},{"date":"2025 Oct","pmid":"40769842","title":"No effect of tetracosactide for treatment of postdural puncture headaches in parturient women: prophylactic use of cosyntropin following accidental dural puncture. Comment on Br J Anaesth 2025; 135: 148-54.","journal":"British journal of anaesthesia"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Amphastar Pharms Inc","companyId":"amphastar-pharms-inc","modality":"Peptide","firstApprovalDate":"1970","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1970-04-22T00:00:00.000Z","mah":"AMPHASTAR PHARMS INC","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:13:14.389811+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}